Oncothyreon, Inc. (NASDAQ:ONTY)

CAPS Rating: 4 out of 5

Results 1 - 12 of 12

Recs

0
Member Avatar pchop12316 (80.71) Submitted: 11/16/2014 7:41:35 PM : Outperform Start Price: $1.70 ONTY Score: -1.98

thumbs up

Recs

0
Member Avatar Tophinater (29.01) Submitted: 11/4/2014 2:51:34 PM : Underperform Start Price: $1.77 ONTY Score: +7.25

yep.

Recs

0
Member Avatar whoodatstockhot (77.36) Submitted: 9/25/2013 12:00:39 PM : Outperform Start Price: $2.28 ONTY Score: -47.50

Strong probability tecemotide succeeds in stage 3 trial-- which would push shares above the $4 dollar mark. Also, nice chance of Merck buyout before then, which would provide significant upside. Potential homerun in the making here.

Recs

0
Member Avatar fatmoneyrz (98.27) Submitted: 9/25/2013 9:52:01 AM : Outperform Start Price: $2.24 ONTY Score: -46.72

Big upside with START2. $3+ valuation in near-term.

Recs

0
Member Avatar stainsolution (22.92) Submitted: 4/4/2012 8:53:38 PM : Outperform Start Price: $4.20 ONTY Score: -108.05

Cancer Bio. Hammered recently. Willing to buy here/ hold for the Ph III run up.

Recs

0
Member Avatar RBuskey106 (42.66) Submitted: 3/14/2012 10:46:05 PM : Outperform Start Price: $4.84 ONTY Score: -112.58

Waiting for Ph 3 stimuvax results...thinking stock may have bottomed.

Recs

1
Member Avatar ccatania13 (< 20) Submitted: 11/21/2011 12:17:13 AM : Outperform Start Price: $7.08 ONTY Score: -148.08

Another stock getting ready to break out. This stock is undervalued right now, and it is prime for the picking. Get ready for shooting star.

Recs

2
Member Avatar siliconvalleyboy (< 20) Submitted: 5/23/2011 1:46:14 AM : Outperform Start Price: $5.56 ONTY Score: -126.20

Very compelling early data from phase II. Existing trial is continuing and data is expected late Q2. Very strong pipeline ahead of them. 1 small molecule with very good chemistry AND a more powerful version of the existing drug, this new drug is not partnered and its value will go up tremendously with the approval, if and when it happens.

Recs

0
Member Avatar RSorak (< 20) Submitted: 4/7/2011 10:12:01 AM : Outperform Start Price: $5.53 ONTY Score: -149.58

See slide 15 of yesterdays Needham conf. Absolutely amazing results.....Zero cancer growth.

Recs

0
Member Avatar Stonesolidpicks (20.44) Submitted: 12/4/2009 5:53:37 PM : Outperform Start Price: $4.84 ONTY Score: -151.43

Cancer drug in Phase 3

Recs

0
Member Avatar mbs9 (< 20) Submitted: 8/27/2009 10:34:35 PM : Outperform Start Price: $5.57 ONTY Score: -168.90

it has some "hidden" gems ready to be announced

Recs

0
Member Avatar TMFBiologyFool (95.60) Submitted: 8/3/2009 2:37:24 PM : Outperform Start Price: $5.65 ONTY Score: -178.20

Promising drugs don't deserve $100 million market caps.

Results 1 - 12 of 12

Featured Broker Partners


Advertisement